New Hope for Glaucoma Patients: Vitamin Supplementation Shows Promise

Researchers are exploring new avenues for glaucoma treatment, shifting focus from solely managing intraocular pressure to addressing metabolic deficiencies within the retina. A recent study suggests that a specific combination of vitamins B6, B9, B12, and choline may offer neuroprotective benefits, potentially slowing the progression of this debilitating eye disease.

Rethinking Homocysteine‘s Role in Glaucoma

For years, elevated levels of homocysteine have been observed in glaucoma patients. However, recent findings challenge the assumption that homocysteine directly contributes to the disease. According to James Tribble, researcher and assistant lecturer at the Department of Clinical Neuroscience at Karolinska Institutet, the study’s first author, Our conclusion is that homocysteine is a spectator during the course of the disease, not an actor. Changed levels of homocysteine can reveal that the retina has lost ability to use certain vitamins required to maintain a healthy metabolism. This insight prompted the inquiry into whether vitamin supplementation could protect the retina.

Preclinical Success: Vitamins Slow Glaucoma in Animal Models

The research team conducted experiments on mice and rats with glaucoma, administering a combination of vitamins B6, B9, B12, and choline. The results where encouraging. In mice with slowly developing glaucoma, the progression of optic nerve damage was significantly slowed. Similarly, in rats with a more aggressive form of the disease, the rate of deterioration was also reduced.

Notably, intraocular pressure was not treated in these experiments. This suggests that the vitamin mix targets the disease through a mechanism distinct from pressure-lowering medications, which are the current standard of care. Glaucoma affects over 76 million people worldwide, and this novel approach could offer a complementary strategy for managing the disease. According to the BrightFocus Foundation, glaucoma is a leading cause of irreversible blindness globally, highlighting the urgent need for new treatment options.

Clinical Trials Underway: Testing the Vitamin Cocktail in Humans

buoyed by the promising preclinical results, researchers have initiated a clinical trial at S:t Erik’s eye hospital in Stockholm. The results are so promising that we have started a clinical trial, where patients are already recruited at S: t Erik’s eye hospital in Stockholm, says James Tribble. The trial includes patients with both primary open-angle glaucoma (a slower progressing form) and pseudoexfoliation glaucoma (a faster progressing form).

The study aims to determine whether the vitamin supplementation can effectively slow the progression of glaucoma in humans, mirroring the positive outcomes observed in animal models. The results of this trial could have significant implications for the future management of glaucoma, potentially offering a new, non-invasive treatment option.

further details about the clinical trial can be found here.

Funding and Publication Details

This research was made possible through funding from several organizations, including the Swedish Research Council, the Eye Fund, Jeansson’s foundations, the Crown Princess Margaret’s Work Board for Visually Impaired, Åke Wiberg Foundation, and Petrus & Augusta Hedlund Foundation.

The complete study, titled “Dysfunctional one-carbon metabolism identifies vitamins B6, B9, B12, and choline as neuroprotective in glaucoma”, authored by James Tribble, Vickie Wong, Kelsey Stuart, Glyn Chidlow, alan Nicol, Anne Rombaut, Alessandro Rabiolo, Anh Hoang, Pei Ying Lee, Carola Rutigliani, Tim Enz, Alessio Canovai, Emma Lardner, Gustav Stålhammar, Christine nguyen, David Garway-Heath, Robert Casson, Anthony Khawaja, bang Bui, and Pete A Williams, was published online in Cell Reports Medicine on may 8, 2025 (doi: 10.1016/j.xcrm.2025.102127).